Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998-2008

British Journal of Haematology

Volumn 157, Issue 1, 2012, Pages 97-104

  Toft, Nina ^a   Schmiegelow, Kjeld ^b   Klausen, Tobias W ^a   Birgens, Henrik ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Acute lymphoblastic leukaemia; Childhood leukaemia; Elderly; Prognostic factors; Treatment

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GLUCOCORTICOID; HEMOGLOBIN; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGE DISTRIBUTION; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER REGISTRY; CAUSE OF DEATH; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CLINICAL PROTOCOL; COHORT ANALYSIS; CONSOLIDATION CHEMOTHERAPY; DENMARK; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GENDER; GROUPS BY AGE; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LYMPHOBLAST; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLOIDY; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SURVIVAL TIME; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DENMARK; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 84858297699     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.09020.x     Document Type: Article

References (30)

1. Bassan, R., Spinelli, O., Oldani, E., Intermesoli, T., Tosi, M., Peruta, B., Rossi, G., Borlenghi, E., Pogliani, E.M., Terruzzi, E., Fabris, P., Cassibba, V., Lambertenghi-Deliliers, G., Cortelezzi, A., Bosi, A., Gianfaldoni, G., Ciceri, F., Bernardi, M., Gallamini, A., Mattei, D., Di, B.E., Romani, C., Scattolin, A.M., Barbui, T. & Rambaldi, A. (2009) Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood, 113, 4153-4162.
2. Boissel, N., Auclerc, M.F., Lheritier, V., Perel, Y., Thomas, X., Leblanc, T., Rousselot, P., Cayuela, J.M., Gabert, J., Fegueux, N., Piguet, C., Huguet-Rigal, F., Berthou, C., Boiron, J.M., Pautas, C., Michel, G., Fiere, D., Leverger, G., Dombret, H. & Baruchel, A. (2003) Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. Journal of Clinical Oncology, 21, 774-780.
3. De Bont, J.M., Holt, B., Dekker, A.W., van der Does-van den Berg, A., Sonneveld, P. & Pieters, R. (2004) Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia, 18, 2032-2035.
4. Bruggemann, M., Raff, T., Flohr, T., Gokbuget, N., Nakao, M., Droese, J., Luschen, S., Pott, C., Ritgen, M., Scheuring, U., Horst, H.A., Thiel, E., Hoelzer, D., Bartram, C.R. & Kneba, M. (2006) Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood, 107, 1116-1123.
5. Campana, D. (2010) Minimal residual disease in acute lymphoblastic leukemia Hematology. American Society of Hematology Education Program, 2010, 7-12.
6. Chessells, J.M., Hall, E., Prentice, H.G., Durrant, J., Bailey, C.C. & Richards, S.M. (1998) The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia, 12, 463-473.
7. Cox, D.R. (1972) Regression models and life-tables (with discussion). Journal of the Royal Statistical Society (B)34, 187-220.
8. Ellison, R.R., Mick, R., Cuttner, J., Schiffer, C.A., Silver, R.T., Henderson, E.S., Woliver, T., Royston, I., Davey, F.R., Glicksman, A.S., Bloomfield, C.D. & Holland, J.F. (1991) The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B. Journal of Clinical Oncology, 9, 2002-2015.
9. Haiat, S., Marjanovic, Z., Lapusan, S., Vekhoff, A., Rio, B., Corre, E., Dimicoli, S., Hirsch, P., Marie, J.P. & Legrand, O. (2011) Outcome of 40 adults aged from 18 to 55years with acute lymphoblastic leukemia treated with double-delayed intensification pediatric protocol. Leukemia Research, 35, 66-72.
10. Hallbook, H., Gustafsson, G., Smedmyr, B., Soderhall, S. & Heyman, M. (2006) Treatment outcome in young adults and children >10years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer, 107, 1551-1561.
11. Holowiecki, J., Krawczyk-Kulis, M., Giebel, S., Jagoda, K., Stella-Holowiecka, B., Piatkowska-Jakubas, B., Paluszewska, M., Seferynska, I., Lewandowski, K., Kielbinski, M., Czyz, A., Balana-Nowak, A., Krol, M., Skotnicki, A.B., Jedrzejczak, W.W., Warzocha, K., Lange, A. & Hellmann, A. (2008) Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. British Journal of Haematology, 142, 227-237.
12. Huguet, F., Leguay, T., Raffoux, E., Thomas, X., Beldjord, K., Delabesse, E., Chevallier, P., Buzyn, A., Delannoy, A., Chalandon, Y., Vernant, J.P., Lafage-Pochitaloff, M., Chassevent, A., Lheritier, V., Macintyre, E., Bene, M.C., Ifrah, N. & Dombret, H. (2009) Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. Journal of Clinical Oncology, 27, 911-918.
13. Hunault, M., Harousseau, J.L., Delain, M., Truchan-Graczyk, M., Cahn, J.Y., Witz, F., Lamy, T., Pignon, B., Jouet, J.P., Garidi, R., Caillot, D., Berthou, C., Guyotat, D., Sadoun, A., Sotto, J.J., Lioure, B., Casassus, P., Solal-Celigny, P., Stalnikiewicz, L., Audhuy, B., Blanchet, O., Baranger, L., Bene, M.C. & Ifrah, N. (2004) Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood, 104, 3028-3037.
14. Kantarjian, H.M., O'Brien, S., Smith, T.L., Cortes, J., Giles, F.J., Beran, M., Pierce, S., Huh, Y., Andreeff, M., Koller, C., Ha, C.S., Keating, M.J., Murphy, S. & Freireich, E.J. (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. Journal of Clinical Oncology, 18, 547-561.
15. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
16. Labar, B., Suciu, S., Zittoun, R., Muus, P., Marie, J.P., Fillet, G., Peetermans, M., Stryckmans, P., Willemze, R., Feremans, W., Jaksic, B., Bourhis, J.H., Burghouts, J.P. & deWitte, T. (2004) Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients ≤50years old in first complete remission: results of the EORTC ALL-3 trial. Haematologica, 89, 809-817.
17. Larson, R.A., Dodge, R.K., Burns, C.P., Lee, E.J., Stone, R.M., Schulman, P., Duggan, D., Davey, F.R., Sobol, R.E., Frankel, S.R., Hooberman, A.L., Westbrook, C.A., Arthur, D.C., George, S.L., Bloomfield, C.D. & Schiffer, C.A. (1995) A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood, 85, 2025-2037.
18. Mohty, M., Labopin, M., Volin, L., Gratwohl, A., Socie, G., Esteve, J., Tabrizi, R., Nagler, A. & Rocha, V. (2010) Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood, 116, 4439-4443.
19. Pui, C.H., Robison, L.L. & Look, A.T. (2008) Acute lymphoblastic leukaemia. Lancet, 371, 1030-1043.
20. Ram, R., Storb, R., Sandmaier, B.M., Maloney, D.G., Woolfrey, A., Flowers, M.E., Maris, M.B., Laport, G.G., Chauncey, T.R., Lange, T., Langston, A.A., Storer, B. & Georges, G.E. (2011) Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica, 96, 1113-1120.
21. Ramanujachar, R., Richards, S., Hann, I., Goldstone, A., Mitchell, C., Vora, A., Rowe, J. & Webb, D. (2007) Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatric Blood and Cancer, 48, 254-261.
22. Rowe, J.M., Buck, G., Burnett, A.K., Chopra, R., Wiernik, P.H., Richards, S.M., Lazarus, H.M., Franklin, I.M., Litzow, M.R., Ciobanu, N., Prentice, H.G., Durrant, J., Tallman, M.S. & Goldstone, A.H. (2005) Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood, 106, 3760-3767.
23. Sallan, S.E. (2006) Myths and lessons from the adult/pediatric interface in acute lymphoblastic leukemia. Hematology. American Society of Hematology Education Program, 2006, 128-132.
24. Schmiegelow, K., Forestier, E., Hellebostad, M., Heyman, M., Kristinsson, J., Soderhall, S. & Taskinen, M. (2010a) Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia, 24, 345-354.
25. Schmiegelow, K., Heyman, M., Gustafsson, G., Lausen, B., Wesenberg, F., Kristinsson, J., Vettenranta, K., Schroeder, H., Forestier, E. & Rosthoej, S. (2010b) The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse. Leukemia, 24, 715-720.
26. Stock, W., La, M., Sanford, B., Bloomfield, C.D., Vardiman, J.W., Gaynon, P., Larson, R.A. & Nachman, J. (2008) What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood, 112, 1646-1654.
27. Storring, J.M., Minden, M.D., Kao, S., Gupta, V., Schuh, A.C., Schimmer, A.D., Yee, K.W., Kamel-Reid, S., Chang, H., Lipton, J.H., Messner, H.A., Xu, W. & Brandwein, J.M. (2009) Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. British Journal of Haematology, 146, 76-85.
28. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2011) WHO classification of Tumours, 4th edn, IARC Press, Lyon, France.
29. Tangen, J.M., Floisand, Y., Haukas, E., Naess, I.A., Skjelbakken, T., Stapnes, C. & Tjonnfjord, G.E. (2010) [Survival in adults with acute lymphoblastic leukaemia]. Tidsskrift for den Norske Laegeforening, 130, 1710-1713.
30. Thomas, X., Boiron, J.M., Huguet, F., Dombret, H., Bradstock, K., Vey, N., Kovacsovics, T., Delannoy, A., Fegueux, N., Fenaux, P., Stamatoullas, A., Vernant, J.P., Tournilhac, O., Buzyn, A., Reman, O., Charrin, C., Boucheix, C., Gabert, J., Lheritier, V. & Fiere, D. (2004) Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. Journal of Clinical Oncology, 22, 4075-4086.